What’s Going On With Sam Altman’s SPAC AltC Stock?

AltC, a special acquisition company headed by Sam Altman, is targeting a merger with Oklo. Oklo is an advanced nuclear fission start-up company which also counts Altman as a board member. The companies announced that they entered into a definitive business combination agreement on July 11, 2023.  If approved and upon closing, the combined company will be listed on the New York Stock Exchange under the ticker symbol "OKLO."

AltC Acquisition Corp. (NYSE:ALCC) shares are moving Monday. The company is scheduled to hold a special meeting of stockholders on Tuesday to approve its proposed business combination with Oklo, Inc. 

The Details:

AltC, a special acquisition company headed by Sam Altman, is targeting a merger with Oklo. Oklo is an advanced nuclear fission start-up company which also counts Altman as a board member. 

The companies announced that they entered into a definitive business combination agreement on July 11, 2023.  If approved and upon closing, the combined company will be listed on the New York Stock Exchange under the ticker symbol “OKLO.”

AltC is one of the top trending tickers on Stocktwits and WallStreetBets ahead of the merger vote, and the stock is moving on heavy volume. According to data from Benzinga Pro, more than 1.835 shares have already been traded in the session, compared to the stock’s 100-day average of less than 743,000 shares.

Related News: What’s Going On With Coinbase Stock After Earnings? 

ALCC Price Action: According to Benzinga Pro, AltC shares are up 0.13% at $14.85 at the time of publication Monday.

Image: Shutterstock

Total
0
Shares
Related Posts
Read More

BioMarin Announced Stable and Durable Annualized Bleed Control for ROCTAVIAN in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; Said 92% of Patients off Prophylaxis at the End of Year 3

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from more than three years of follow up from its ongoing global Phase 3 GENEr8-1 study of ROCTAVIANTM (valoctocogene roxaparvovec), an investigational one-time gene therapy for the treatment of adults with severe hemophilia A.

BMRN